QSAM - QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial
- Treating patients with primary or secondary bone cancer remains goal, says company CEO
- Radiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cells
- QSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients
QSAM Biosciences (OTCQB: QSAM), a company developing a new class of drugs called radiopharmaceuticals, is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its proprietary radiopharmaceutical technology: CycloSam(R).
“This is an important milestone for QSAM,” said QSAM cofounder and CEO Douglas R. Baum (https://ibn.fm/GcD0R). “Successfully treating patients with primary or secondary bone cancer remains an area of...
NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.